A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction
Overall, the incidence of stomach cancer worldwide is declining with geographical variation.
However, an increase in the incidence rate of adenocarcinoma of esophagogastric junction,
called cardia or AEG has been observed in recent years. AEG may represent a specific
histopathological and biologic entity. In the treatment AEG there is argument over whether
proximal gastractomy(PG) or total gastractomy (TG) should be done. The quality of life (QOL)
of the patients following TG or PG arouses people's attention. The purpose of this study was
to evaluate differences of the quality of life in patients undergoing total gastrectomy or
proximal gastrectomy for adenocarcinoma of esophagogastric junction.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Change in QOL (Quality of Life)
From preoperative following gastrectomy, as measured with the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-STO22 questionnaires.
China: Food and Drug Administration